You are now leaving the current website.

The site you are accessing is maintained by a third party over whom CSL Behring has no control. CSL Behring does not review, approve, or necessarily endorse viewpoints, inferences, or conclusions stated in or implied by the content of this site. CSL Behring is not responsible for third-party content or the consequences of your use thereof.

Do you want to continue?

HEMGENIX®-logo-bg HEMGENIX® (etranacogene dezaparvovec)

*The annualized bleed rate (ABR) for all bleeds decreased from an average of 4.1 for prophylaxis during the lead-in period to 1.9 in months 7–18 after treatment, an ABR ratio of 0.46 (95% CI: 0.26, 0.81).

DNA helix with man and woman holding hands mobile-banner-img

David

Factor IX level of
37% for years

Patient portrayal; HEMGENIX not
intended for women

DNA helix

HEMGENIX: The first ever FDA-approved

gene therapy for hemophilia B

STEP INTO A WORLD OF

ELEVATED FACTOR IX LEVELS THAT LAST FOR YEARS

A one-time infusion delivers significant bleed protection*

Explore efficacy

Explore treatment guides, locate a HEMGENIX administration site, and more

Discover resources

*The annualized bleed rate (ABR) for all bleeds decreased from an average of 4.1 for prophylaxis during the lead-in period to 1.9 in months 7–18 after treatment, an ABR ratio of 0.46 (95% CI: 0.26, 0.81).

Magnifying glass icon

Which of your patients might benefit from HEMGENIX?

Find out
Speech bubble icon

Get more information or request to speak with a CSL Behring representative

Connect with us

HAVE ADDITIONAL QUESTIONS?

Connect with CSL Behring Medical Affairs to find additional information and ask questions.

Top of Page

IMPORTANT SAFETY INFORMATION

Warning and Precautions

Infusion Reactions

Infusion reactions, including hypersensitivity reactions and anaphylaxis, may occur. Monitor during administration and for at least 3 hours after end of infusion. If symptoms occur, slow or interrupt administration. Re-start administration at a slower infusion once resolved.

Hepatotoxicity/Hepatocellular Carcinoma

Post-dose, monitor for elevated transaminase levels. Consider corticosteroid treatment should elevations occur. The integration of liver-targeting AAV vector DNA into the genome may carry the theoretical risk of hepatocellular carcinoma development. For patients with preexisting risk factors for hepatocellular carcinogenicity, perform regular (eg, annual) abdominal ultrasound and alpha-fetoprotein testing following administration.

Immune-mediated neutralization of the AAV5 vector capsid

Preexisting neutralizing anti-AAV antibodies may impede transgene expression at desired levels.

Monitoring Laboratory Tests

In addition to monitoring liver function, monitor for Factor IX activity and Factor IX inhibitors after administration.

Adverse Reactions

The most common adverse reactions (incidence ≥5%) were elevated ALT, headache, blood creatine kinase elevations, flu-like symptoms, infusion-related reactions, fatigue, nausea, malaise, and elevated AST.

Indication

HEMGENIX®, etranacogene dezaparvovec-drlb, is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who:

  • Currently use Factor IX prophylaxis therapy, or
  • Have current or historical life-threatening hemorrhage, or
  • Have repeated, serious spontaneous bleeding episodes.

HEMGENIX is for single use intravenous infusion only.

Contraindications: None.

Please see full prescribing information for HEMGENIX.

To report SUSPECTED ADVERSE REACTIONS, contact the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.